Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Key Highlights
- ➤Sagimet to participate in Guggenheim Healthcare Innovation Conference on November 9, 2026
- ➤Sagimet granted 63,600 inducement stock options to two newly hired employees
- ➤Options have a ten-year term and vest over four years
- ➤Denifanstat is being evaluated in a U.S. Phase 3 trial for moderate to severe acne
FOSTER CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key lipid synthesis regulator, for acne, today announced that management will participate in the Guggenheim 3(rd) Annual Healthcare Innovation Conference on Monday, November 9, 2026, in Boston, MA with a fireside chat at 10:30am ET (link here).
In connection with the hiring of two employees, the Compensation Committee of Sagimet’s Board of Directors approved that an inducement grant of 63,600 stock options in aggregate to purchase shares of the Company’s Series A common stock be granted on October 28, 2026 to the newly hired employees.
Get started
Create a free account to read the full story.